International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)
The 2024 update to the international pancreatic cyst guidelines, which adds faster cyst growth, new diabetes and pancreatitis to the warning signs, allows surveillance to stop in some older patients with small stable cysts, and grades each recommendation by the strength of the evidence.
Overview
Evidence-graded revision of the Fukuoka guidelines by the International Association of Pancreatology, meeting in Kyoto. High-risk stigmata are retained, with an enhancing mural nodule of 5 mm or more, main duct of 10 mm or more, obstructive jaundice and positive cytology as indications for surgery in fit patients. Worrisome features now include cyst growth of 2.5 mm or more per year, new-onset or worsening diabetes and acute pancreatitis, alongside the earlier criteria.
The guideline addresses when surveillance can be stopped (after five years of stability in cysts under 2 cm in patients who would not be surgical candidates), the role of cyst fluid molecular analysis, management after resection, and the need for randomised trials of surveillance strategies.
- New worrisome features: cyst growth 2.5 mm or more per year, new-onset or worsening diabetes, acute pancreatitis.
- Surveillance may stop after five years of stability in small cysts in patients unfit for surgery.
- Recommendations graded by evidence quality for the first time.
The current international standard for deciding which pancreatic cysts to operate on, which to watch and for how long.
- Most recommendations still rest on low-quality retrospective evidence.
- Differences from the European and American guidelines persist, particularly on stopping surveillance.
Similar pages
not linked directly; found by shared links- Key paperEuropean evidence-based guidelines on pancreatic cystic neoplasms (2018)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- Key paperRevised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaGlucose monitor data as an early pancreatic cancer signal
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaStop watching stable low-risk pancreatic cysts after five years
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- PersonDiane M. Simeone
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaNew diabetes after 50 plus weight loss triggers a pancreatic cancer check
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- IdeaAI that spots pancreatic cancer on scans taken a year before diagnosis
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.
- PersonRichard Schulick
Shares Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatic ductal adenocarcinoma.